Caution Recommended For New Anti-Obesity Drug In Children

A new class of anti-obesity drugs that suppresses appetite by blocking cannabinoid receptors in the brain could also suppress the adaptive rewiring of the brain necessary for neural development in children, studies with mice have indicated. One such drug, rimonabant (trade name Acomplia) has been developed by Sanofi-Aventis and is awaiting approval for use in the U.S., and other pharmaceutical companies are developing similar drugs.

Mark Bear and colleagues published their findings in the May 8, 2008, issue of the journal Neuron, published by Cell Press.

the rest...

http://www.medicalnewstoday.com/articles/106749.php

I know what you are thinking... cannabis...

http://en.wikipedia.org/wiki/Cannabinoid_receptor

grz-

Tweet